Research Nester released a report titled “Renal Disease Treatment Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global renal disease treatment market in terms of market segmentation by disease, by treatment, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The renal disease treatment market is anticipated to record a significant CAGR of about 6.5% during the forecast period, i.e., 2019-2027. The market is segmented by disease, by treatment, by end user and by region, out of which, the disease segment is further sub-segmented into acute kidney failure, chronic kidney disease [CKD], end-stage renal disease [ESRD] and others. On the basis of disease, the chronic kidney disease segment is estimated to hold the largest share in the market. This can be attributed to the growing incidences of CKD among people, especially among the elderly population.

The largest share in the renal disease treatment market is anticipated to be held by the market in North America on account of adoption of unhealthy lifestyle among the population leading to large patient population in the region. The growing demand for improved healthcare services and treatment methods along with rising healthcare expenditure are additional factors estimated to support the market growth. Further, the market in Asia-Pacific region is anticipated to grow at the highest rate as a result of growing awareness in countries such as China, Japan and India about various renal disorders and expanding healthcare infrastructure in the region.

Growing Number of Kidney Diseases and Related Disorders to Drive the Market Growth

According to a report published by the Centers for Disease Control and Prevention in 2019, the prevalence of adults living in the United States with CKD is around 15%, which comprises of about 37 million people. Renal disorders, along with other diseases showing a direct impact on the kidney such as diabetes and hypertension are anticipated to result in the growth of renal disease treatment market. On the other hand, the stringent regulatory rules and policies by the government regarding approval of medical drugs and devices is anticipated to hamper the market growth during the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global renal disease treatment market which includes company profiling of Novartis AG (NOVN), Abbott (ABT), Amgen Inc. (AMGN), Baxter (BAX), Keryx Biopharamceuticals, Inc., Pfizer (PFE), Fresenius Medical Care, Otsuka America Pharmaceutical, Inc., Veloxis Pharmaceuticals, Inc. and Affymax Inc. (AFFY). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global renal disease treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.